Elena Buendia Gonzalez

Médico Especialista
Specialty:
Urology
Serving specialties:
  • Urología
913445056
E-mail: Elena.buendia@quironsalud.es
Hospitals where he/she works:
  • Hospital Universitario Fundación Jiménez Díaz
Consultation: CEP QUINTANA
Opening times: De 8:00 a 15:00 L-J-V
General Information
Experience
  • Internal Medicine Resident at Virgen de la Salud Hospital in Toledo 2005-2010
  • Specialist in Urology Department in Toledo in URO Oncology 2010-2014
  • Member of the Transplant Unit from 2008-October 2014
  • Assistant Specialist in Urology Department at Jiménez Díaz Foundation University Hospital from October 2024 to present
  • Member of the Uro-Oncology Unit dedicated to Urothelial Cancer since 2016
Degree
  • LICENCIADO EN MEDICINA Y CIRUGIA
Techniques

Laparoscopic and Robotics in carcinoma Urothelial

Research and teaching
  • 2025 42756493BLC1003: Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer. Janssen Research & Development, LLC. EU CT Number: 2021-004144-22. Principal Investigator.
  • 2024 UTOPIA: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients with Low Grade (LG) Non muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence. UroGen Pharma Ltd. IND: 167943. EU CT Number: 2023-507261-25. Sub-Investigator.
  • 2023 ORION: A Phase 3, Single-Arm Study to Evaluate the Efficacy and Safety of Oncofid-P-B (Paclitaxel-Hyaluronic Acid Conjugate) Administered Intravesically to Patients with Bcg-Unresponsive Carcinoma In Situ of The Bladder With Or Without Ta-T1 Papillary Disease. Eudra Ct N: 2022-001236-28. Fidia Farmaceutici S.P.A.
  • Sub-Investigator.
  • 2023 SSANTROP. A Phase 2 prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive NMIBC patients.. Protocol code: APRO07-2022. EudraCT No: 2022-002998-28. APRO.
  • Sub-investigator.
  • 2022 ENVISION: A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence. UroGen Pharma Ltd. IND 138749. Sub-Investigator.
  • 2022 ALBAN: An open label, randomized, phase 3 trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus Calmette Guerin) bladder instillation in BCG-naive patients with high-risk non-muscle invasive Bladder Cancer. UNICANCER Group Tumor: GETUG / AFU. Protocol n° UC-0160/1717 (AFU-GETUG 37)EudraCT n°: 2017-004512-19. Sub-Investigator.
  • 2021 URANUS TRIAL: Neo-adjuvant versus Adjuvant chemotherapy in Upper tract Urothelial Carcinoma: A feasibility phase 2 randomize clinical Trial. Sub-Investigator. EUOG (European Uro-oncology Group). Principal Investigator.
  • 2019 ENCORE-01: Phase I2b Clinical Trial: Treatment of high-risk non-muscle infiltrating bladder tumors with IMUNO BCG Moreau RJ as prophylaxis for recurrence and progression. Sub-Investigator.

Publications
  • Consequences of BCG shortage for endovesical instillation and its effect on recurrence-free survival in high-risk non-infiltrating bladder tumours. X. Pérez Aizpurua, Juan Ignacio Monzó Gardiner, J. Maqueda Arellano, E. Buendía González, Leslie Cuello Sánchez, J.J. Tufet Jaumot. Anales de la Real Academia Nacional de Medicina, ISSN 0034-0634, Nº 138, 3, 2021, págs. 237-245.
  • A Systematic Review on the Current Landscape of T1 Bladder Cancer Substaging. Pérez-Aizpurua X, Monzó-Gardiner JI, Popescu OB, Buendía-González E, Cuello- Sánchez L, Cañadas-Granados M, Tufet I Jaumot JJ, Ruiz de Castroviejo-Blanco J, Osorio-Ospina F, Cabello-Benavente R, González-Enguita C Urology. 2024 Dec;194:310-326. doi: 10.1016/j.urology.2024.10.013. Epub 2024 Oct 9. PMID: 39389368.
  • BCG shortage for intravesical instillation is associated with early tumoral recurrence in patients with high-risk non-muscle invasive bladder tumours. Pérez-Aizpurua X, Monzó-Gardiner JI, Maqueda-Arellano J, Buendía-González E, Cuello-Sánchez L, Tufet I Jaumot JJ, Alonso-Román J, Gómez-Jordana Mañas B, Ruiz de Castroviejo Blanco J, Osorio Ospina F, Cabello Benavente R, González-Enguita C Actas Urol Esp (Engl Ed). 2023 May;47(4):250-258. English, Spanish. Doi: 10.1016/j.acuroe.2023.01.005. Epub 2023 Feb 6. PMID: 36754206.
  • Cólico renal. Opciones terapéuticas actuales. Beneficios de la litotricia extracorpórea inmediato o précoz (leoci). González Enguita C, Bueno Serrano G, Tabares Jiménez, J, Charry Gónima P, Buendía González E.. Cuadernos de Urología. Temas de Formación para el Médico de Atención Primaria. AÑO 2015, N º 68, 2015. NISSN 1135-3163
  • Other multiple papers and book chapters.
Communications and Presentations

Clinical teaching collaborator. Moderator at National Congress 2021-2024

Awards and certifications

Robotic Surgeon Accreditation Nov2024